Your browser doesn't support javascript.
loading
Left atrial assist device for heart failure with preserved ejection fraction: initial results with torque control mode in diastolic heart failure model.
Miyagi, Chihiro; Kuban, Barry D; Flick, Christine R; Polakowski, Anthony R; Miyamoto, Takuma; Karimov, Jamshid H; Starling, Randall C; Fukamachi, Kiyotaka.
Affiliation
  • Miyagi C; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Kuban BD; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. kubanb@ccf.org.
  • Flick CR; Electronics Core, Medical Device Solutions, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. kubanb@ccf.org.
  • Polakowski AR; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Miyamoto T; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Karimov JH; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Starling RC; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Fukamachi K; Department of Cardiovascular Medicine, Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
Heart Fail Rev ; 28(2): 287-296, 2023 03.
Article in En | MEDLINE | ID: mdl-33931816
ABSTRACT
A novel pump, the left atrial assist device (LAAD), is a device specifically for the treatment of heart failure with preserved ejection fraction (HFpEF). The LAAD is a mixed-flow pump that is implanted in the mitral position and delivers blood from the left atrium to the left ventricle. During the development process, we aimed to explore whether device activation in torque control (TC) mode would improve the function of the LAAD. The TC mode causes adjustment of the pump speed automatically during each cardiac cycle in order to maintain a specified torque. In this study, we tested four different TC settings (TC modes 0.9, 1.0, 1.25, and 1.5) using an in vitro mock circulatory loop. Mild, moderate, and severe diastolic heart failure (DHF) conditions, as well as normal heart condition, were simulated with the four TC modes. Also, we evaluated the LAAD in vivo with three calves. The LAAD was implanted at the mitral position with four TC settings (TC modes 0.9, 1.0, 1.1, 1.2). With LAAD support, the in vitro cardiac output and aortic pressure recovered to normal heart levels at TC 1.25 and 1.5 even under severe DHF conditions with little pump regurgitation. The TC mode tested in vivo with three calves, and it also showed favorable result without elevating the left ventricular end-diastolic pressure. These initial in vitro and in vivo results suggest that the TC mode could be potentially effective, and the LAAD could be a treatment option for HFpEF patients.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Heart-Assist Devices / Heart Failure, Diastolic / Heart Failure Limits: Animals / Humans Language: En Journal: Heart Fail Rev Journal subject: CARDIOLOGIA Year: 2023 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Heart-Assist Devices / Heart Failure, Diastolic / Heart Failure Limits: Animals / Humans Language: En Journal: Heart Fail Rev Journal subject: CARDIOLOGIA Year: 2023 Document type: Article Affiliation country: United States
...